FindTrial
Sign In

compare the results of tablet and injection tranexamic acid for pigmentation over face

A compare the efficacy of oral tranexamic acid versus intralesional tranexamic acid in management of melasma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/07/044450
Enrollment
100
Registered
2022-07-28
Start date
Unknown
Completion date
Unknown
Last updated
2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L811- Chloasma

Interventions

Intervention1: Tranexamic acid injection: intradermal tranexamic acid injection, . 3 injections at an interval of 4 weeks. Control Intervention1: oral tranexamic acid: tranexamic acid 250 mg twice a d

Sponsors

Military hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged 18-60 years with clinical diagnosis of melasma.

Exclusion criteria

Exclusion criteria: 1. History of bleeding disorders 2. Patient taking oral anticoagulants, hormonal drugs like estrogen, progesterone, oral contraceptive pills and other female hormonal analogues. 3. Past or family history of thrombotic disease like DVT. 5. Patients with known allergy to tranexamic acid. 6. Pregnant and lactation mothers. 8. Patients with any other facial dermatoses. 9. History of any treatment for melasma in the past 6 months.

Design outcomes

Primary

MeasureTime frame
reduction in mMASI scoreTimepoint: At presentation and follow-up at 4, 8 , 12 and 24 weeks—

Secondary

MeasureTime frame
patient satisfaction scoreTimepoint: at presentation and 6 months after treatment—

Countries

India

Contacts

Public ContactEeshaan ranjan

Military hospital Jammu

eeshaan.ranjan@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026